SciELO - Scientific Electronic Library Online

 
vol.62 issue3Serum TSH level stability after 5 years in euthyroid adults at low risk for thyroid dysfunctionPotential role of sorafenib as neoadjuvant therapy in unresectable papillary thyroid cancer author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

Share


Archives of Endocrinology and Metabolism

Print version ISSN 2359-3997On-line version ISSN 2359-4292

Abstract

CURY, Sarah Santiloni et al. Graves’ ophthalmopathy: low-dose dexamethasone reduces retinoic acid receptor-alpha gene expression in orbital fibroblasts. Arch. Endocrinol. Metab. [online]. 2018, vol.62, n.3, pp.366-369.  Epub May 17, 2018. ISSN 2359-3997.  http://dx.doi.org/10.20945/2359-3997000000044.

Objective:

Graves’ ophthalmopathy (GO) is an autoimmune disease that leads to ocular proptosis caused by fat accumulation and inflammation, and the main treatment is corticosteroid therapy. Retinoid acid receptor-alpha (RARα) seems to be associated with inflammation and adipocyte differentiation. This study aimed to assess the effect of glucocorticoid treatment on orbital fibroblasts of GO patient treated or not with different glucocorticoid doses.

Materials and methods:

Orbital fibroblasts collected during orbital decompression of a female patient with moderately severe/severe GO were cultivated and treated with 10 nM and 100 nM dexamethasone (Dex). rRARα gene expression in the treated and untreated cells was then compared.

Results:

Fibroblast RARα expression was not affected by 100 nM Dex. On the other hand, RARα expression was 24% lower in cells treated with 10 nM Dex (p < 0.05).

Conclusions:

Orbital fibroblasts from a GO patient expressed the RARα gene, which was unaffected by higher, but decreased with lower doses of glucocorticoid.

Keywords : Receptors; retinoic acid; gene expression; graves ophthalmopathy.

        · text in English     · English ( pdf )